1. AIDSinfo. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services; 2018. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/31/adverse-effects-of-arv [accessed 11 September 2020].
2. European AIDS Clinical Society (EACS). EACS guidelines, Version n.10.0. EACS; 2019. http://www.eacsociety.org/files/2019_guidelines-10.0-english.pdf [accessed 11 September 2020].
3. Società Italiana Malattie Infettive e Tropicali (SIMIT). Utilizzo dei farmaci antiretrovirali e gestione diagnostico-clinica delle persone con infezione da HIV-1; 8 edizione, 2017 [Use of antiretroviral drugs and diagnostic-clinical management of people with HIV-1 infection; 8 edition, 2017]. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf [accessed 11 September 2020].
4. Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
5. ATLAS-M Study Group. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial;Fabbiani;J Antimicrob Chemother,2018